

# Pneumococcal Conjugate Vaccine (PCV13, Prevnar®)

Table 1. PCV13 Recommended Schedule

Age at First Dose	Total # of Doses	Schedule
2-6 months	4	<ul style="list-style-type: none"> <li>2, 4, and 6 months of age, 8 weeks apart</li> <li>Booster dose at age 12-15 months</li> </ul>
7-11 months	3	<ul style="list-style-type: none"> <li>2 doses, 8 weeks apart</li> <li>Booster dose at 12-15 months, with a 2-month interval after the second dose</li> </ul>
12-23 months	2	<ul style="list-style-type: none"> <li>2 doses, 6-8 weeks apart</li> </ul>
24-59 months (healthy children)	1	<ul style="list-style-type: none"> <li>1 dose for healthy children</li> </ul>
24-71 months (high risk)	2	<ul style="list-style-type: none"> <li>2 doses, 6-8 weeks apart if child is at high risk</li> </ul>
6 years and older (high risk)	1	<ul style="list-style-type: none"> <li>Administer in conjunction with PPSV23.</li> </ul>
65 years and older	1	<ul style="list-style-type: none"> <li>Administer in conjunction with PPSV23.</li> </ul>

## PCV13 General Recommendations:

- Recommended for routine vaccination for all children aged 2-59 months.
- Recommended schedules for PCV13 vary with the child's age (**See Table 1**) and the presence of underlying conditions.
- Administer 1 dose of PCV13 to all healthy children aged 24-59 months who have not received at least 1 dose of PCV13 on or after age 12 months.
- Recommended for routine vaccination of all adults 65 years and older. PCV13 should be administered along with PPSV23 but not simultaneously. (**See Table 4**).
- Recommended for adults aged 19 years and older with certain high-risk conditions (**See Table 3**).

## PCV13 Recommendations for Immunocompromised Children 6 – 18 Years and High- Risk Adults:

- Children aged 24-59 months with underlying medical conditions should receive 1 dose of PCV13 if 3 doses were received previously. Two (2) doses of PCV13 are needed for children who previously received less than 3 doses.
- PCV13 is recommended for children 6 years thru 18 years with high-risk conditions who are at increased risk for IPD because of sickle cell disease, HIV infection or other immunocompromising conditions, cochlear implants or cerebrospinal fluid leaks, regardless of whether they have previously received PCV7 or PPSV23. (**See Table 2 for schedule**)
- Adult 19 years and older with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants should receive a dose of PCV13 followed by a dose of PPSV. (**See Table 3 for schedule**)



## Contraindications

- A severe allergic reaction (e.g. anaphylaxis) to any component of Prevnar 13, Prevnar (Pneumococcal 13-Valent Conjugate Vaccine [Diphtheria CRM<sub>197</sub> Protein]) or any diphtheria toxoid-containing vaccine.

## Precautions

- Premature infants:** Apnea following intramuscular vaccination has been observed in some infants born prematurely. The decision to administer should be based on consideration of the individual infant's medical status, and the potential benefits and possible risks of vaccination.

## Adverse Reactions

- Local (injection site):** redness, swelling, tenderness.
- Systemic (general):** fever, decreased appetite, irritability, increased sleep, decreased sleep.

COM-PR/B71-VPCV-V2 (10/15/15)

**Table 2: PCV 13 and PPSV recommended schedule for immunocompromised children aged 6 through 18 years.**

Has the person previously received PPSV23?	PCV13 Schedule
<b>No</b>	<ul style="list-style-type: none"> <li>Administer 1 dose of PCV 13, followed by a dose of PPSV23 8 weeks later.</li> <li>A second dose of PPSV is recommended 5 years after the first PPSV23 dose for children with certain medical conditions.*</li> </ul>
<b>Yes</b>	<ul style="list-style-type: none"> <li>Administer 1 dose of PCV13 at least 8 weeks after the last dose of PPSV23.</li> <li>A second dose is recommended at least five years after the first dose of PPSV23*</li> <li>These children should not receive more than 2 doses before the age of 65.</li> </ul>

\*A second dose is indicated for only children with the following conditions: functional or anatomical asplenia, immunocompromised conditions (e.g. HIV, leukemia, lymphoma, Hodgkin disease, chronic renal failure, nephrotic syndrome, general malignancy, iatrogenic immunosuppression, solid organ transplant, and multiple myeloma).

**Table 3: Recommended PCV13 and PPSV23 schedule for high-risk adults aged 19 years and older.**

Has the person previously received PPSV23?	PCV13 Schedule
<b>Yes</b>	<ul style="list-style-type: none"> <li>Administer 1 dose of PCV13 one or more years after PPSV23</li> <li>If an additional dose of PPSV23 is required, it can be given at least 8 weeks after the PCV13 and at least 5 years after the last PPSV23.</li> <li><b>Note:</b> a second dose of PPSV23 is <b>not required</b> for persons with cochlear implants or CSF leaks until age 65 years or older.</li> </ul>
<b>No</b>	<ul style="list-style-type: none"> <li>Administer 1 dose of PCV13 followed by PPSV23 eight (8) weeks later</li> <li>Administer a 2<sup>nd</sup> dose of PPSV23 5 years later.</li> <li><b>Note:</b> a second dose of PPSV23 is <b>not required</b> for persons with cochlear implants or CSF leaks until age 65 years or older.</li> </ul>

**Table 4: Recommended PCV13 and PPSV23 schedule for adults aged 65 years and older.**

Has the person previously received PPSV23?	PCV13 Schedule
<b>No</b>	<ul style="list-style-type: none"> <li>Administer PCV13 at age 65 years or older, then PPSV23 one year later.</li> </ul>
<b>Yes. After age 65 years</b>	<ul style="list-style-type: none"> <li>Administer PCV13 at least 1 year after PPSV23 dose.</li> </ul>
<b>Yes. Before age 65 years</b>	<ul style="list-style-type: none"> <li>Administer PCV13 at least 1 year after PPSV23; administer 2<sup>nd</sup> PPSV23 1 year later.</li> <li>The 2<sup>nd</sup> dose of PPSV23 should be administered at least 5 years after 1st dose.</li> </ul>